source
- Setara Biosciences launches with $90 million to pursue Charcot-Marie-Tooth and other rare-disease therapiesSetara Biosciences announced its formation on Friday, backed by $90 million of financing to advance a pipeline of experimental medicines. The company’s first candidate targets the genetic disorder…
- Aspen Neuroscience raises $140M IPO to advance Parkinson’s cell therapyAspen Neuroscience, a San Diego biotechnology company, completed an initial public offering, selling roughly 9.4 million shares at $15 each and raising about $140.6 million. The capital will be di…